1. KDIGO (Kidney Disease: Improving Global Outcomes). (2012). KDIGO
Clinical Practice Guidelinefor Anemia in Chronic Kidney Disease.Kidney International Supplements, 2(4): 288-335. 2. Lerma EV. (2013). Anemia of Chronic Disease and Renal Failure. http://emedicine.medscape.com/article/1389854-overview. November 2014]. 3. NKUDIC (National
Kidney
and
Urologic
Diseases
[diakses
19
Information
Clearinghouse). (2008). Anemia in Kidney Disease and Dialysis. Bethesda:
National Institutes of Health Publication. 4. National Kidney Foundation. (2001). NKF-KDOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: Update 2000. Am J Kidney Dis, 37(1):182-238. 5. Stevens LA, Coresh J, Greene T,&Levey AS. (2006). AssessingKidney Function Measuredand Estimated Glomerular Filtration Rate. N Engl J Med, 354:2473-2483. 6. BC Medical Association & Kidney Foundation of Canada. (2008). Chronic Kidney Disease Identification, Evaluation and Management of Patients: Guidelines & Protocols. Vancouver: BC Health Guide. 7. Perhimpunan Nefrologi Indonesia (PERNEFRI). (2011). Pengkajian Status Besi dan Terapi Besi. Konsensus Manajemen Anemia pada Penyakit Ginjal Kronik. Ed II. 8. Tong EM& Nissenson AR. (2001). Erythropoietin and Anemia. Semin Nephrol, 21:190-203. 9. Moore E&Bellomo R. (2011). Erythropoietin (EPO) in Acute Kidney Injury. Annals of Intensive Care, 1:3-13. 10. Donnelly S. (2001). Why is Erythropoietin Made in the Kidney? The Kidney Functions as a Critmeter. Am J Kidney Dis, 38:415-425. 11. Tarif N. (2002). Anemia Management in Patients with Chronic Renal Disease: Current Recommendations. Saudi J Kidney Dis Transplant, 13: 331335. 12. Nurko S. (2006). Anemia in Chronic Kidney Disease: Causes, Diagnosis, Treatment. Cleveland Clinic Journal pf Medicine, 73: 289-297. 13. Erslev AJ & Besarab A. (1997). Erythropoietin in the Pathogenesis and Treatment of the Anemia of Chronic Renal Failure. Kidney Int, 51: 622-630. 14. Mezzano S, Droguett A, Burgos ME, Ardiles LG, Flores CA, Aros CA, Caorsi I, Vio CP, Ruiz-Ortega M&Egido J. (2003). Renin-angiotensin System 26
27
Activation
and
Interstitial
Inflammation
in
Human
Diabetic
Nephropathy.Kidney Int,(Suppl): S64-S70.
15. Marsden PA. (2009).Treatment of Anemia in Chronic Kidney Disease Strategies Based on Evidence. N Engl J Med, 361: 2089-2090. 16. Vos FE, Schollum JB, Coulter CV, Doyle TC, Duffull SB&Walker RJ. (2011). Red Blood Cell Survival in Long-term Dialysis Patients, 58(4):591598. 17. Mehdi U & Toto RD. (2009). Anemia, Diabetes and Chronic Kidney Disease. Diabetes Care, 32(7): 1320-1326. 18. Stenvinkel P& Alvestrand A. (2002). Inflammation in End-stage Renal Disease: Sources, Consequences and Therapy. Semin Dial, 15:329-337. 19. Steinvinkel P. (2001). The Role of Inflammation in the Anaemia of End-stage Renal Disease. Nephrol Dial Transplant, 16(7):36-40. 20. Remuzzi GR& Ingelfinger JR. (2006). Correction of Anemia: Payoffs and Problems. N Engl J Med,355: 2144-2145. 21. Kalantar Zadeh K, Rodriguez RA& Humphreys MH. (2004). Association Between Serum Ferritin and Measures of Inflammation, Nutrition and Iron in Haemodialysis Patients. Nephrol Dial Transplant, 19: 141-149. 22. Nakanishi T& Kuragano T. (2010). Importance of Ferritin for Optimizing Anemia Therapy in Chronic Kidney Disease. Am J Nephrol, 32: 439-446. 23. Senol E, Ersoy A, et al. (2008). Oxidative Stress and Ferritin Levels in Haemodialysis Patients. Nephrol Dial Transplant, 23: 665-672. 24. Locatelli F, Aljama P& Barany P. (2004). Revised European Best Practice Guidelines for the Management of Anaemia in Patients with Chronic Renal Failure. Nephrol Dial Transplant, 19(Suppl 2): ii1-i47. 25. Bakta IM. (2006). Hematologi Klinik Ringkas. Jakarta: EGC. 26. Weiss G& Goodnough LT. (2005). Anemia of Chronic Disease. N Engl J Med,352: 1011-1023. 27. Bakhshi S & Besa EC. (2011). Aplastic Anemia. http://emedicine. medscape.com/article/198759-overview. [diakses tanggal 1 Desember 2013]. 28. Fehr T, Ammann P& Garzoni D. (2004). Interpretation of ErythropoietinLevels in Patients with Various Degrees of Renal Insufficiency and Anemia.Kidney Int, 66: 1206-1211. 29. Rambod M, Kovesdy CP& Kalantar-Zadeh K. (2008). Combined High SerumFerritin and Low Iron Saturation in Hemodialysis Patients: the Role ofInflammation. Clin J Am Soc Nephrol, 3: 1691-1701. 30. Tessitore N, Girelli D& Campostrini N. (2010). Hepcidin is not Useful as aBiomarker
25:3996-4002. 31. Drueke TB, Locatelli F& Clyne N. (2006). Normalization of Hemoglobin Level in Patients with Chronic Kidney Disease and Anemia. N Engl J Med, 355(20):2071-2084. 32. Singh AK, Szczech L& Tang KL. (2006). Correction of Anemia with Epoetin Alfa in Chronic Kidney Disease. N Engl J Med, 355(20):2085-2098. 33. Toto RD, Pichette V, Navarro J, Brenner R, Carroll W, Liu W& Roger S. (2004). Darbepoetin Alfa Effectively Treats Anemia in Patients with Chronic Kidney Disease with De Novo Every-other-week Administration. Am J Nephrol, 24: 453-460. 34. Ling B, Walczyk M, Agarwal A, Carroll W, Liu W& Brenner R. (2005). Darbepoetin Alfa Administered Once MonthlyMaintains Hb Concentrations in Patients with Chronic Kidney Disease. Clin Nephrol, 63: 327-334. 35. Macdougall IC& Cooper AC. (2002). Erythropoietin Resistance: The Role of Inflammation and Pro-inflammatory Cytokines. Nephrol Dial Transplant, 17:39-43. 36. USRDS System. (2010). USRDS 2010 Annual Data Report: Atlas of Chronic KidneyDisease and End-Stage Renal Disease in the United States. NationalInstitutes of Health 2010, National Institute of Diabetes and Digestiveand Kidney Diseases. 37. Agarwal R. (2010). Individualizing Decision-makingresurrecting the Doctor-patient Relationship in the Anemia Debate. Clin J Am Soc Nephrol, 5: 1340-1346. 38. Nangaku M. (2006). Chronic Hypoxia and TubulointerstitialInjury: A Final Common Pathway toEnd-Stage Renal Failure. JASN, 17(1): 17-25.